Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 5/20 | 0.40 |
| ▸ | CDK1 | P06493 | 4/20 | 0.40 |
| ▸ | CCND1 | P24385 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87859 | 0.91 | CDK2 (0.45) | CDK4CDK2CDK1CCND1MAPK14 | |
| SCHEMBL69317 | 0.91 | EIF2AK2 (0.43) | CDK4CDK2CDK1CCND1MAPK14 | |
| SCHEMBL68164 | 0.90 | MAPK14 (0.44) | CDK4CDK2CDK1CCND1MAPK14 | |
| SCHEMBL67728 | 0.86 | CDK4 (0.48) | CDK4CDK2CDK1CCND1TTK | |
| SCHEMBL69453 | 0.86 | CDK4 (0.48) | CDK4CDK2CDK1CCND1TTK | |
| SCHEMBL67727 | 0.86 | CDK4 (0.48) | CDK4CDK2CDK1CCND1TTK | |
| SCHEMBL84568 | 0.85 | MAPK14 (0.41) | MAPK14 | |
| SCHEMBL69402 | 0.83 | CDK2 (0.47) | CDK4CDK2CDK1CCND1MAPK14 | |
| SCHEMBL68690 | 0.83 | CDK2 (0.47) | CDK4CDK2CDK1CCND1MAPK14 | |
| SCHEMBL68689 | 0.83 | CDK2 (0.47) | CDK4CDK2CDK1CCND1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CDK4 12/4885CDK2 20/4885CDK1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.